by Stacey Hawkins | Aug 2, 2018 | Immunotherapies
Attack Of The Mono- & Polyclonals Monoclonal antibody (mAb) therapeutics burst onto the healthcare scene twenty years ago. They remain one of the most versatile and effective therapies available for a whole range of diseases including different types of cancers,... 
by Stacey Hawkins | May 4, 2017 | Genomics
The Skinny On DNA Testing 23andMe (Mountain View, CA) recently found itself back in the limelight after the disease risk section of its mail-in DNA kit received an OK from the FDA. The Silicon Valley biotech had to halt sales of its direct-to-consumer genetics testing... 
by Stacey Hawkins | Sep 17, 2015 | Devices
THINKING OUTSIDE OF THE BODY Last WEEKLY’s focus on Duchenne muscular dystrophy got us to thinking, what products are available for those with limited mobility? A new type of medical device called a powered exoskeleton certainly caught our eye. Originally... 
by Stacey Hawkins | Jun 25, 2015 | Metabolic & Cardiovascular Disease
$23 Billion Blockbuster? The PCSK9 inhibitor buzz keeps rolling, especially since sitting before the FDA Advisory Committee earlier this month. Amgen’s (Thousand Oaks, CA) Repatha and Sanofi’s (Paris, France) Praluent are a new class of cholesterol lowing... 
by Stacey Hawkins | Apr 16, 2015 | Uncategorized
The Subtypes of Breast Cancer Hearing your doctor utter the words HER2-positive, HR-positive, triple-negative, or BRCA mutation can be devastating—even for the most resilient person. Simply put, all are linked to breast cancer. Breast cancer is complex and a diagnosis...
